2-isopropyl-3,4,5,6-tetrahydropyrimidine | 80676-53-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-isopropyl-3,4,5,6-tetrahydropyrimidine
• 英文别名: 2-isopropyl-1,4,5,6-tetrahydropyrimidine；2-(Propan-2-yl)-1,4,5,6-tetrahydropyrimidine；2-propan-2-yl-1,4,5,6-tetrahydropyrimidine
• CAS: 80676-53-5
• 化学式: C₇H₁₄N₂
• 分子量: 126.202
• InChiKey: KZCLFWYVLDNEMU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  24.4
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-isopropyl-3,4,5,6-tetrahydropyrimidine 在 palladium/alumina 作用下， 以76%的产率得到(9CI)-2-(1-甲基乙基)-嘧啶
  参考文献：
  名称：

  Pews, Richard Garth, Heterocycles, 1988, vol. 27, # 8, p. 1867 - 1872

  摘要：

  DOI：
• 作为产物：
  描述：

  (Z)-3-(3-aminopropylamino)-4-methylpent-2-enenitrile 以71%的产率得到
  参考文献：
  名称：

  LANDOR, S. R.;LANDOR, P. D.;FOMUM, Z. T.;MBAFOR, J. T., HETEROCYCLES, 1981, 16, N 11, 1889-1892

  摘要：

  DOI：

文献信息

• Pyridobenzazepine compounds and methods for inhibiting mitotic progression
  申请人：Claiborne F. Christopher

  公开号：US20080045501A1

  公开（公告）日：2008-02-21

  This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.

  这项发明涉及用于治疗癌症的化合物和方法。具体而言，该发明提供了抑制枢纽激酶的化合物，包括这些化合物的药物组合物，以及使用这些化合物治疗癌症的方法。
• [EN] ALLOSTERIC ACTIVATORS OF THE ALPHA1A -ADRENERGIC RECEPTOR<br/>[FR] ACTIVATEURS ALLOSTÉRIQUES DU RÉCEPTEUR ALPHA1A-ADRÉNERGIQUE
  申请人：CLEVELAND CLINIC FOUND

  公开号：WO2020219720A1

  公开（公告）日：2020-10-29

  The present invention relates to compounds that are activators of the Alpha1A-Adrenergic Receptor (α1A-AR) and methods of using such compounds: for treating neurological conditions, for cardio-protection, and for treating other conditions. In certain embodiments, the α1A-AR activator compound is a compound of Formula I. In certain embodiments, the neurological condition is Alzheimer's disease, benign prostatic hyperplasia, memory loss, depression, or Parkinson's disease.

  本发明涉及激活Alpha1A-肾上腺素受体（α1A-AR）的化合物及使用这些化合物的方法：用于治疗神经系统疾病、心脏保护和治疗其他疾病。在某些实施例中，α1A-AR激活剂化合物是式I的化合物。在某些实施例中，神经系统疾病是阿尔茨海默病、良性前列腺增生、记忆力下降、抑郁症或帕金森病。
• Antifungal agents
  申请人：Greenlee Mark L.

  公开号：US20100113439A1

  公开（公告）日：2010-05-06

  Novel derivatives of enfumafungin are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antifungal agents and/or inhibitors of (1,3)-β-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating and/or preventing fungal infections and associated diseases and conditions.

  本文披露了恩福马富金的新型衍生物，以及它们的药用盐、水合物和前药。还公开了包含这些化合物的组合物、制备这些化合物的方法以及将这些化合物用作抗真菌剂和/或(1,3)-β-D-葡聚糖合酶抑制剂的方法。这些公开的化合物、它们的药用盐、水合物和前药，以及包含这些化合物、盐、水合物和前药的组合物，可用于治疗和/或预防真菌感染及相关疾病和病况。
• Preparation of 2-alkylpyrimidines
  申请人：The Dow Chemical Company

  公开号：US04493929A1

  公开（公告）日：1985-01-15

  2-Alkylpyrimidines are obtained in a one step reaction which comprises the dehydrogenation of a 2-alkyltetrahydropyrimidine over a supported noble metal catalyst under conditions which do not generate water and in which no water is added.

  2-烷基嘧啶可以通过一步反应得到，该反应包括在不产生水和不添加水的条件下，在贵金属催化剂的支持下对2-烷基四氢嘧啶进行脱氢。
• THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS
  申请人：Biju J. Purakkattle

  公开号：US20080090823A1

  公开（公告）日：2008-04-17

  Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.

  本发明涉及的是一种新型的化合物，其结构式如下：其中包括Substituent A和Substituent B，其药学上可接受的盐和溶剂化合物。Substituent A的基团包括杂环芳基、芳基、杂环烷基、环烷基、炔基、烯基、氨基烷基、烷基或氨基。Substituent B的基团包括芳基和杂环芳基。本发明还涉及一种治疗趋化因子介导疾病的方法，例如癌症、血管生成、眼部血管生成性疾病、肺部疾病、多发性硬化症、类风湿性关节炎、骨关节炎、中风和缺血再灌注损伤、疼痛（例如急性疼痛、急性和慢性炎症性疼痛和神经病理性疼痛），使用化合物IA的方法。